Table 1_Continuing immune checkpoint inhibitors beyond progression versus switching to non

A single-center, retrospective study of 169 patients with advanced gastric or gastroesophageal junction cancer who progressed after first-line immuno-chemotherapy. The research compares outcomes for patients continuing ICI therapy versus switching to non-ICI regimens, reporting progression-free and overall survival metrics. The dataset was authored by Guangxi Wang and last updated in June 2026.

Use Cases

• Comparing progression-free survival between treatment strategies based on the reported median PFS of 4.4 vs. 3.0 months.
• Analyzing overall survival benefit from continuing immunotherapy based on the reported median OS of 9.5 vs. 6.4 months.
• Identifying patient subgroups who benefit most from continued ICI therapy based on features like PD-L1 expression or first-line therapy response mentioned in the description.
• Evaluating the safety profile of second-line treatment strategies based on the described manageable and comparable safety between groups.

Strengths

• Includes data from 169 patients, providing a substantive real-world cohort.
• Reports specific survival outcomes, including hazard ratios (e.g., PFS HR=0.47) and p-values.
• Analysis includes multivariable adjustment and propensity score matching, suggesting methodological rigor.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is from a single-center study, which may limit generalizability.

Provenance

Source

figshare

Collection Method

Retrospective, single-center study.

Freshness

Last updated 2026-06-03 04:51:12; freshness should be verified.